An in vitro model was used to investigate the potential for different structural forms of endogenous antigen to be processed and presented by major histocompatibility complex class H molecules. For this purpose the class IIrestricted presentation of an immunodominant epitope of hen egg lysozyme Mixing experiments with different antigenpresenting cells indicated that the HEL-(46-61) determinant was derived from endogenous antigen rather than by reuptake of shed or secreted HEL determinants. We conclude that MIIC class H molecules can present some antigenic determinants derived from endogenous proteins that are sequestered in the
HEL), or (iii) anchored on the cell surface as an integral membrane protein (mHEL). The corresponding sHEL, ER-HEL, and mHEL gene products were expressed as predicted except that HEL determinants accumulated in the culture supernatant as well as on the cell membrane of mHELtransfected cells. Class II-positive cells endogenously expressing all three forms of HEL antigen constitutively presented the immunodominant HEL-(46-61) determinant with differential efficiency (mHEL, sHEL > ERHEL) to a class II-restricted T hybridoma. A second T hybridoma recognized endogenous HEL-(46-61) determinants constitutively presented on sHEL(hi) and mHEL transfectants but not on sHEL(lo) or ERHEL transfectants. The formation of HEL-(46 61)/I-Ak complexes in the ERHEL and sHEL(lo) transfectants was therefore limiting. Mixing experiments with different antigenpresenting cells indicated that the HEL-(46-61) determinant was derived from endogenous antigen rather than by reuptake of shed or secreted HEL determinants. We conclude that MIIC class H molecules can present some antigenic determinants derived from endogenous proteins that are sequestered in the ER/salvage compartment as well as distally transported in the form of secretory or membrane antigens.
Major histocompatibility complex (MHC) class II molecules are the ligands for presentation of processed foreign antigens to T cells (1) . Normally, class II-restricted antigens are derived from an exogenous source (2, 3) and the major site of class II loading with processed exogenous antigens is thought to reside in post-Golgi acidified endosomes (4) (5) (6) . In contrast, endogenously derived peptides appear to assemble in the endoplasmic reticulum (ER) with class I MHC molecules (7) (8) (9) . Thus, separate pathways of processing and presentation of antigens restricted by class I and class II molecules have been suggested (10) (11) (12) . Nevertheless, determinants derived from certain endogenous antigens can be presented in association with class II rather than class I molecules (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . In most instances this process involves cell surface antigens (13) (14) (15) (16) (17) 24) , although some viral proteins can use a cytoplasmic pathway of presentation following endosomal processing (18, 20) . With possible exceptions (23) 
MATERIALS AND METHODS
Gene Constructs. The plasmids encoding sHEL(lo) (SAY1) and ERHEL (SAYMK2) have been described (26) . The plasmid encoding sHEL(hi) (pSVG-MT/HEL) (27) was used in some experiments. The carboxyl-terminal sequence encoded within the ERHEL plasmid includes the residues Lys-AspGlu-Leu (KDEL), which have been characterized as a retention sequence allowing the retrieval of soluble proteins, including HEL (26) , from the salvage compartment into the ER of transfected cells (26, 28, 29) . Construction of the mHEL gene is given in the legend to Fig. 1 .
Transfection. For transfections the I-Ak a-and (3-chain genes and a selectable marker gene (pSV2neo) were first introduced by electroporation into class II-negative, M12.C3 B-lymphoma cells (30) . Supertransfection of I-Ak-positive transfectants was also carried out by electroporation using a second selectable marker gene (pSV2gpt) and the constructs encoding ERHEL, sHEL(hi/lo), or mHEL. Sublines and clones of each of the transfectants expressing equivalent levels of I-Ak were generated by cell sorting or limiting dilution.
ELISA and Metabolic Labeling. The HEL content of culture supernatants and cell lysates was assayed by ELISA (27) of the HEL cDNA followed by a 14-aa reporter sequence containing a linear epitope of c-Myc, and the 6 C-terminal residues SEKDEL. The sHEL(hi) plasmid (pSVG-MT/HEL) encodes the genomic HEL gene transcribed from the mouse metallothionein (MT-1) promoter, which is more active than the adenovirus major late promoter in B-cell transfectants. The mHEL gene comprises the complete HEL coding sequence joined in frame to a portion of the H-2Kb cDNA encoding a part of the connecting peptide as well as the transmembrane (TM) and cytoplasmic (CY) domains of this class I molecule. The hybrid mHEL gene is transcribed from a metallothionein promoter and is linked covalently to the selectable marker gene gpt. The predicted mHEL protein contains the complete 129-aa sequence of native HEL followed by the junctional residues ED and a further 86aa derived from the connecting stalk (21aa), transmembrane domain (24aa), and cytoplasmic region (41 aa) of the murine class I moleculeH-2Kb.
hybridomas with previously defined specificity for HEL-(46-61) (Fig. 3 ). Both T hybridomas (3A9 and A2.2B2) produced maximal amounts of IL-2 following stimulation with I-Ak_ positive M12.C3 B-lymphoma cells expressing mHEL in the absence of exogenous HEL (Fig. 3 A, B , and H).
A similar degree of T-cell activation was observed when cells expressing sHEL(hi)/I-Ak were tested for constitutive expression of HEL-(46-61) (Fig. 3 C and E) . The sHEL(lo)/ I-Ak and ERHEL/I-Ak transfectants, however, stimulated only 3A9 and did not stimulate A2.2B2 unless provided with an exogenous source of HEL (Fig. 3 D and G) . The constitutive presentation of the HEL-(46-61) determinant by the sHEL(lo)I)Ak transfectant was saturating for the 3A9 response ( Fig. 3D) , whereas there was no detectable response of A2.2B2 under the same conditions. The most likely explanation for the lack of detectable stimulation of A2.2B2 by sHEL(lo)/I-Ak transfectants was its less sensitive doseresponse curve compared with that of 3A9 (Fig. 3F ) rather than any unusual property of 3A9 per se.
Like sHEL(lo)/I-Ak cells, ERHEL/I-Ak transfectants did not stimulate the A2.2B2 T hybridoma unless HEL was added ( Fig. 3 B, D, and G) . Moreover, cells expressing ERHEL/1-Ak were not saturating in their stimulation of 3A9, as shown by the capacity of exogenous HEL to induce further IL-2 production by this T hybridoma (Fig. 3G) (Fig. 3 D, E , and H), given theminimum concentration of exogenous HEL required to trigger 3A9 (10-50 ng/ml) and A2.2B2 (0.1-1 jug/ml) using the I-Ak-transfected M12.C3 APCs (Fig. 3D, F , and G). Moreover, coculture ofI-Ak transfectants for 10 days in medium containing HEL at 0.1,1, or 5 ng/ml did not result in detectable presentation of HEL446-61) determinants to 3A9 (data not shown). To address this question more formally, experiments involving mixed APCs were carried out. The sHELlo)/I-Ak, ERHELIJ-Ak, or mHEL/IAktransfectants were cultured in chambers containing a microporous membrane inserted in the wells of a 24-well cluster tray so that the membrane was just above the floor of the culture well. I-Akexpressing reporter APCs (M12.C3 cells) were distributed on the floor of the same culture well so that HEL molecules were freely diffusible across the membrane separating the upper and lower chambers of the well. After 72 hr of coculture the insert containing the test source of HEL was removed and the reporter cells were assayed for presentation of HEL446-61) (Fig. 4A) . No presentation of HEL446-61) was observed when the ERHEL/ I-Ak, sHELIo)/I-Ak, or mHEL/I-Ak transfectants were the sole source of HEL in the upper chamber, whereas a control source of purified HEL was readily presented by reporter APCs to 3A9 under the same conditions (Fig. 4A ).
To verify these findings under conditions of direct coculture of APCs, mixing experiments were performed in which M12.C3 cells expressingI-Ak but negative for m HEL were mixed with cells expressing m HEL but negative forI-Ak (Fig.  4B) . Under conditions of several cell densities and various culture times (24 and 48 hr) there was no detectable stimulation of either A2.2B2 or 3A9 when 1:1 mixtures of these cell populations were used (Fig. 4B and data not shown) . In contrast, cocultures of the T hybridomas with the mHEL/ I-Ak transfectants were maximally stimulatory. processed and presented in association with class II MHC molecules (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . The way in which membrane expression and intracellular localization of such endogenous antigens influence their availability for class II-restricted presentation, remains unclear, however. To clarify these issues, we studied the well-defined antigen HEL, since the activation of T cells by soluble HEL determinants such as HEL-(46-61) constitutes a paradigm of class II-restricted antigen presentation involving endosomal uptake and processing of exogenous antigen (2, 5, 32) . Using transfectants expressing HEL molecules in secreted, ER-localized, or membrane-bound form, we have shown that T cells can recognize this epitope in a class II-restricted manner when it is presented either endogenously or via the classical endosomal pathway for exogenous antigen. Thus we support the view that the rigid class I/II dichotomy perceived for the MHC-restricted presentation of endogenous versus exogenous antigens is not absolute (18) (19) (20) (21) (22) (23) .
Nevertheless there are some well-defined differences in the preferred pathway for processing and presentation of antigens for class I-and class II-restricted presentation. Class I molecules are believed to associate in the ER with processed antigens derived from the cytoplasm (7) (8) (9) 11) . Class II molecules, on the other hand, are thought to associate in post-Golgi endosomes with processed antigens derived from the endosomal compartment (2-6, 11). The invariant chain (Ii) associates with newly synthesised class II molecules in the ER and may prevent the binding of antigen with class II molecules until the dissociation of class II/Ii complexes in a post-Golgi compartment (35, 36) .
In the current experiments the ability of the ERHEL/I-Ak_ transfected cells to present endogenously derived HEL-(46-61) clearly points to the existence of a mechanism for assembly of class II molecules with processed intracellular antigens derived from the ER/salvage compartment. Presentation of ERHEL determinants could arise from the generation and assembly of antigen determinants with class II Proc. Natl. Acad. Sci. USA 88 (1991) molecules in both the ER and the pre-Golgi sorting/salvage compartment, since molecules with the KDEL signal are known to shuttle between these compartments (25, 28, 29) .
Consistent with this possibility, protein degradation is known to occur in the ER (37) even though creation of endogenous HEL-(46-61) need not always involve proteolysis of HEL molecules (32) . Moreover, there is evidence for (23) as well as against (12) the loading of class II molecules with peptide antigen in the ER. On the other hand, if HEL was derived from the cytoplasm or from leakage of small amounts of ERHEL antigen into the Golgi and post-Golgi vacuoles, then processing and presentation of HEL-(46-61) might occur later in cellular transport. In principle it should be possible to experimentally distinguish endosomal from nonendosomal processing of ERHEL by studying the chloroquine and brefeldin A sensitivity of ERHEL processing. However, when such experiments were performed in our system, the results were difficult to interpret because of the multiple treatments of APCs necessary to eliminate constitutive class II/HEL-(46-61) complexes from the cell surface (by antibody or peptide blocking) prior to drug manipulation of APCs. Hence we could not resolve definitively whether the constitutive HEL-(46-61) presentation by the ERHEL transfectants involved loading of class II molecules in the ER or in a distal vacuolar compartment. The relatively inefficient presentation of HEL-(46-61) derived from ERHEL molecules could therefore arise from (i) failure to reveal the HEL-(46-61) determinant in the ER, (ii) competition for class II assembly between HEL-(46-61) and Ii in the ER (35, 36) , or (iii) the limited availability of ERHEL antigen leaking from the ER into the endosomal compartment. Nevertheless, irrespective of the site of class II antigen loading, the data do demonstrate that endogenous self-antigens localized within the pre-Golgi compartment are potentially accessible for class TI-restricted presentation.
The implication from the finding with ERHEL transfectants is that the mechanisms of constitutive presentation of HEL-(46-61) in the sHEL/I-Ak and mHEL/I-Ak transfectants may also involve class II assembly with HEL determinants created during pre-Golgi vesicular transport as well as during transport distal to the ER/salvage compartment. The greater efficiency of presentation by the mHEL transfectants probably results from the greater level of expression of HEL determinants by these transfectants and the potential for mHEL molecules to undergo endocytosis from the cell surface, thereby making them available for endosomal antigen processing.
Collectively these data indicate that endogenously synthesized secreted, membrane-bound, and intracellular selfantigens sequestered in the ER can be available for presentation by class II molecules. A threshold intracellular concentration of self-antigen appears necessary for endogenous presentation by class II molecules, and this concentration is higher for ER-trapped antigen. This notion has important implications for self-tolerance in the T-cell repertoire and the development of autoimmunity. The preference of class II molecules for presentation of antigens that intersect the distal vacuolar compartment (endosomes) could serve to limit the extent of antigenic competition for class II occupancy by endogenously derived antigens (38, 39) . Nevertheless, the ability of some sequestered endogenous antigens to be presented by class II molecules, despite their low abundance, may facilitate T-cell self-tolerance by exploiting the greater ligand-sensitivity of developing T cells compared with mature T cells (40) .
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